Great news on Friday: the paper about our most advanced therapeutic program against Idiopathic Pulmonary Fibrosis just got published in Nature Biotechnology: nature.com/articles/s4158…
Congratulations to the Team! 👏
@InSilicoMeds@biogerontology
New research published in Aging describes how @InSilicoMeds PandaOmics software was able to predict molecular targets for new drugs to Rx both aging & age-associated diseases like Alzheimer’s, Parkinson’s, cirrhosis, RA & more…
#AI#pharmafiercebiotech.com/medtech/insili…
We just did something fun. Discovered a target without a structure, used AlphaFold-predicted structure for SBDD, got a weak hit in about 30 days. @A_Aspuru_Guzik@MLevitt_NP2013#alphafold
Check out and critique the pre-print as we wait for better hits arxiv.org/abs/2201.09647
Today @InSilicoMeds is thrilled to announce our most important news to date - our antifibrotic program has now progressed to the First-in-Human stage! prnewswire.com/news-releases/…
Today we are ready to reveal our new partner - Usynova Pharmaceuticals Ltd. Follow us to see another collaboration to be announced soon. @InSilicoMedsprnewswire.com/news-releases/…
Dear Friends, we have some exciting news! @InSilicoMeds just nominated a preclinical candidate (PCC) for kidney fibrosis, an age-related process implicated in multiple diseases. prnewswire.com/news-releases/…
We're always looking for new ways to accelerate innovation and help growers. Our partnership with @InSilicoMeds will unlock the transformative power of AI to make this happen.
#AI4AG#AgTech#SyngentaCropProtection
We @InSilicoMeds are extremely proud to announce that the first fully AI-designed #drug candidate is entering the clinic! Both the biological #target and the molecules were discovered using #AI. For more info please watch our video documentary: youtu.be/AOJfkDu5nC4